CVRx Inc. Common Stock (CVRX)
Stock · NASDAQ · Health Care
$1.31as of 10/16/2026
Price chart
Active signals
CVRX Signal Track Record
How signals performed across all stocks →What CVRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 48 | +2.5% | 50% | September 30, 2026 |
| Bollinger Band Breakdown | 24 | +15.7% | 63% | September 23, 2026 |
| Bollinger Band Breakout | 24 | +3.1% | 63% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -6.3% | 38% | April 22, 2026 |
| Any 20-session window (baseline) | -1.2% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CVRX
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signalin…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 223
- Website
- www.cvrx.com/
Fundamentals
- 1-day range
- $1.26$1.39
- Market cap
- $157.62M
- P/E (trailing)
- —
- P/E (forward)
- -0.69
- EPS (trailing)
- $-1.97
- Dividend yield
- —
- Beta
- 0.71
- Avg. volume
- 943.0K
How CVRx Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
CVRx Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CVRXCVRx Inc. Common Stock$1.3▼ 6.47%Market cap $157.62MP/E —$1.28$11.3
- STIMNeuronetics Inc. Common Stock$1.88▼ 3.33%Market cap $156.57MP/E —$0.8$3.44
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3▼ 0.99%Market cap $163.52MP/E —$2.86$6.61
- RCELAvita Medical Inc. Common Stock$13.04▼ 2.76%Market cap $146.19MP/E —$3.22$13.73
- APYXApyx Medical Corporation Common Stock$2.55▼ 0.39%Market cap $174.35MP/E —$2.32$5.08
- LUCDLucid Diagnostics Inc. Common Stock$0.478▼ 8.08%Market cap $193.54MP/E —$0.5$1.63
- MBOTMicrobot Medical Inc. Common Stock$0.95▲ 0.00%Market cap $120.90MP/E —$0.99$3.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CVRX CVRx Inc. Common Stock | $157.62M | — | $1.3 | ▼ 6.47% | $1.28$11.3 |
| STIM Neuronetics Inc. Common Stock | $156.57M | — | $1.88 | ▼ 3.33% | $0.8$3.44 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3 | ▼ 0.99% | $2.86$6.61 |
| RCEL Avita Medical Inc. Common Stock | $146.19M | — | $13.04 | ▼ 2.76% | $3.22$13.73 |
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $2.55 | ▼ 0.39% | $2.32$5.08 |
| LUCD Lucid Diagnostics Inc. Common Stock | $193.54M | — | $0.478 | ▼ 8.08% | $0.5$1.63 |
| MBOT Microbot Medical Inc. Common Stock | $120.90M | — | $0.95 | ▲ 0.00% | $0.99$3.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- CVRx Reports Q2 2026 Results: Full Earnings Call Transcriptbenzinga · 10/12/2026
- Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.ChartMill · 9/30/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/30/2026
- CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026Yahoo · 9/29/2026
- CVRx To Present Barostim Data And Clinical Research At HFSA Annual Scientific Meeting 2026Benzinga · 9/29/2026
- CVRx Appoints John Landry as Chief Financial OfficerYahoo · 9/21/2026
- CVRx Appoints John Landry CFO, Effective Oct. 12, Succeeding Jared OasheimBenzinga · 9/21/2026
- Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains?Yahoo · 9/17/2026
Insider Activity
Insider Actions →- Binkowski Brent · August 13, 2026 · Buy26.2K @ $2.91
- Binkowski Brent · August 12, 2026 · Sale1.3K @ $2.55
- Hill, Mitch C. · June 1, 2026 · Grant8.7K
- Jain Mudit K. · June 1, 2026 · Grant11.2K
- Jain Mudit K. · June 1, 2026 · Grant8.7K
- Ballinger Kevin J. · June 1, 2026 · Grant11.2K
- Ballinger Kevin J. · June 1, 2026 · Grant8.7K
- Nielsen Kirk G. · June 1, 2026 · Grant11.2K
- Nielsen Kirk G. · June 1, 2026 · Grant8.7K
- Martha Shadan · June 1, 2026 · Grant11.2K
- Martha Shadan · June 1, 2026 · Grant8.7K
- Hill, Mitch C. · June 1, 2026 · Grant11.2K
- Joseph P. Slattery · June 1, 2026 · Grant11.2K
- Joseph P. Slattery · June 1, 2026 · Grant8.7K
- DALE MICHAEL D · June 1, 2026 · Grant36.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 14.50M
- Total value held
- $136.12M
- Institutional holders
- 96
- Unknown4.02M
- Unknown2.03M
- Unknown1.03M
- Unknown1.01M
- Unknown911.3K
- Unknown707.0K
- Unknown630.8K
- Unknown572.0K
- Unknown429.5K
- Unknown427.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
CVRx Appoints John Landry as CFO
CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.
CVRx Appoints John Landry as CFO. CVRx announced that John Landry will become chief financial officer, effective Oct. 12, replacing Jared Oasheim. The change follows a routine leadership transition and may bring new financial oversight to the company. The appointment is noted by market watchers but does not alter the current trading range or technical signals. Investors can monitor how the new CFO’s approach aligns with the company’s financial goals.